Yesterday evening an article was published in the local Antwerp newspaper GVA. It stated Flemish Minister of the Environment Jo Brouns (CD&V) has granted a permit for the Waterkracht project. As a result, all chemical companies in the Port of Antwerp will use purified wastewater to cool their production processes starting at the end of 2027. Earlier on the target was to start commercial operations early 2027 and this is still reflected in our earnings model. We will overhaul our model once it is...
We update our Zealand model following the company's recent CMD held in December 2025. Zealand outlined its plans to become a generational metabolic health company, as well as sharing clear targets with 5 product launches in the next 5 years, and to have 10+ clinical programs by 2030. Our model update incorporates adjusted milestone timing from Roche, removes dapiglutide, as well as a few small tweaks on the rare disease pipeline. All in all, this brings us to a new TP of DKK 960 (from DKK 1,120)...
Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 5 February 2026 Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary Additionally, the completion of Vepakum is expected to take place shortly. Following these milestones, Injeplast and Amber remain subject to closing, together with Vepakum. Vepakum Vepakum operates two facilities in São Paulo, ...
Fagron verkrijgt goedkeuring van lokale autoriteiten voor de overname van Vepakum in Brazilië en rondt de overname van Magilab in Hongarije af Gereglementeerde informatie - voorwetenschapNazareth (België)/Rotterdam (Nederland), 5 februari 2026 – 7:00 AM CET Fagron verkrijgt goedkeuring van lokale autoriteiten voor de overname van Vepakum in Brazilië en rondt de overname van Magilab in Hongarije af Daarnaast wordt verwacht dat de overname van Vepakum op korte termijn zal worden afgerond. Na deze mijlpalen blijven Injeplast en Amber, samen met Vepakum, onderhevig aan afronding. Vepakum V...
Ekopak just announced a long term strategic partnership with an unnamed European infrastructure partner for the development of (large) WaaS projects. Many details are still unknown and management was not (yet) available for comments. The partnership introduces a minimum of €150m in off balance sheet funding over the next three years that will be deployed through dedicated asset companies financed with senior non recourse debt and majority equity from the infrastructure partner. As part of the pa...
Inside information: Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 January 2026 – 7:00 AM CET Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America Fagron, the leading global player in pharmaceutical compounding, is pleased to announce the completion of University Compounding Pharmacy (UCP), a 503A pharmaceutical compounder focused on the health and wellness segment in California. The transacti...
Voorkennis: Fagron kondigt de afronding van de overname van University Compounding Pharmacy in Noord-Amerika aan Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 12 januari 2026 – 7:00 AM CET Fagron kondigt de afronding van de overname van University Compounding Pharmacy in Noord-Amerika aan Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, kondigt met genoegen de afronding van de overname van University Compounding Pharmacy (UCP), een 503A-farmaceutisch bereider gericht op de gezondheids- en welzijnssector in Californië, aan. De t...
Disclosure of notification received from BNP Paribas Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 09 January 2026 – 5:40 PM CET Disclosure of notification received from BNP Paribas Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from BNP Paribas Asset Management Holding. Notification by BNP Paribas Asset Management Holding On 7 January 2026, Fagron received a notification that the shareholding of BNP Paribas Asset Management Holding, crossed the disclosure threshold of...
Openbaarmaking van kennisgeving ontvangen van BNP Paribas Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 9 januari 2026 – 17u40 CET Openbaarmaking van kennisgeving ontvangen van BNP Paribas Fagron heeft een kennisgeving ontvangen op grond van de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen van BNP Paribas Asset Management Holding. Kennisgeving van BNP Paribas Asset Management Holding Op 7 januari 2026 heeft Fagron een kennisgeving ontvangen dat het aandeelhouderschap van BNP Paribas Asset Managem...
Zealand announced that it entered into an agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support its Metabolic Frontier 2030 strategy, to deliver five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030.The platform supports advanced characterization, simulation, and generative AI modelling for drug discovery and design. Financial terms were not disclosed. DKK 1,120 TP and BUY maintained.
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Press release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark’s flagship AI supercomputer, gives Zealand Pharma access to unprecedented computational power, enabling large-scale modeling, prediction, and optimization of drug candidatesAgreement will support Zealand Pharma’s Metabolic Frontier 2030 strategy ...
Fagron announces the completion of Purifarma Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 January 2026 – 7:00 AM CET Fagron announces the completion of Purifarma Fagron, the leading global player in pharmaceutical compounding, is pleased to announce the completion of Purifarma in Brazil, an important milestone in executing our disciplined M&A strategy. The completion of this transaction follows competition clearance by CADE, the Brazilian antitrust authority, last October, and will strengthen Fagron’s scalable, high-quality platform, in line ...
Fagron kondigt de afronding van de overname van Purifarma aan Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 6 januari 2026 – 7:00 AM CET Fagron kondigt de afronding van de overname van Purifarma aan Fagron, de toonaangevende wereldwijde speler in farmaceutische bereidingen, is verheugd om de afronding van de overname van Purifarma in Brazilië aan te kondigen. Een belangrijke mijlpaal in de uitvoering van onze gedisciplineerde M&A-strategie. De afronding van Purifarma volgt op de goedkeuring van CADE, de Braziliaanse mededingingsautoriteit, in oktober vo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.